Wednesday, April 8, 2020 Daily Archives

Takeda, CSL and others working on plasma-derived COVID-19 therapies

by

Takeda says COVID-19 therapy accord will work on TAK-888 and other plasma-derived meds developed by its partners. The Japanese drug firm teamed up with CSL Behring, Biotest, BPL Group, LFB and Octapharma this week. The aim is to turn blood plasma from recovered patients into treatments for COVID-19. The initial focus will be TAK-888, an anti-SARS-CoV-2 polyclonal hyperimmune immunoglobulin medicine. But a Takeda spokeswoman told us the idea is to work on all in-progress development efforts. “Companies collaborating as part…

April 8, 2020

Inovio’s COVID-19 vaccine enters clinic buoyed by VGXI manufacturing success

by

Inovio Pharmaceuticals has asked VGXI to scale-up manufacturing of a potential DNA vaccine against COVID-19 after an initial production run provided materials for a Phase I trial that began this week. The first dosing of INO-4800, a DNA vaccine candidate designed to prevent COVID-19, took place this week after the US Food and Drug Administration (FDA) accepted the company’s Investigational New Drug (IND) application. The Phase I study of INO-4800 will enroll up to 40 healthy adult volunteers at the…

April 8, 2020